EGFR and non-small cell lung carcinoma: In a phase-III trial (ADAURA trial) of patients with stage IB to IIIA epidermal growth factor receptor mutation-positive NSCLC, Wu et al. [12] found that DFS was significantly longer among those who received osimertinib than among those who received placebo.